Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,414
archived clinical trials in
Overactive Bladder

A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Phoenix, AZ
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
La Mesa, CA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
La Mesa, CA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Modesto, CA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Modesto, CA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
San Bernardino, CA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
San Bernardino, CA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Torrance, CA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Aurora, CO
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Denver, CO
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Longmont, CO
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Longmont, CO
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Waterbury, CT
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Waterbury, CT
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Aventura, FL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Aventura, FL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Clearwater, FL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Fort Myers, FL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Miami, FL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Ocala, FL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Ocala, FL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Pembroke Pines, FL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Sarasota, FL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Atlanta, GA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Melrose Park, IL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Melrose Park, IL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Indianapolis, IN
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Jeffersonville, IN
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Newburgh, IN
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Newburgh, IN
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Lexington, KY
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Albany, NY
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Albany, NY
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Kingston, NY
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Kingston, NY
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Poughkeepsie, NY
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Salisbury, NC
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Salisbury, NC
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Winston-Salem, NC
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Springfield, OR
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Springfield, OR
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Bala Cynwyd, PA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Bala Cynwyd, PA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Lancaster, PA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Lancaster, PA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Sellersville, PA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Sellersville, PA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Providence, RI
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Providence, RI
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Simpsonville, SC
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Simpsonville, SC
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Nashville, TN
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Dallas, TX
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Richmond, VA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Tacoma, WA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Surrey,
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Surrey,
Click here to add this to my saved trials
Health Interventions in Men Undergoing Radical Prostatectomy
Health Interventions in Men Undergoing Radical Prostatectomy- A Randomized Controlled Clinical Trial
Status: Enrolling
Updated:  1/25/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Health Interventions in Men Undergoing Radical Prostatectomy
Health Interventions in Men Undergoing Radical Prostatectomy- A Randomized Controlled Clinical Trial
Status: Enrolling
Updated: 1/25/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Linkage Analysis in Interstitial Cystitis
Genetic Studies of Urologic Chronic Pelvic Pain Syndrome
Status: Enrolling
Updated:  2/2/2017
Jordan D Dimitrakoff
mi
from
Boston, MA
Linkage Analysis in Interstitial Cystitis
Genetic Studies of Urologic Chronic Pelvic Pain Syndrome
Status: Enrolling
Updated: 2/2/2017
Jordan D Dimitrakoff
mi
from
Boston, MA
Click here to add this to my saved trials
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects With Overactive Bladder and a Diagnosis of Detrusor Overactivity - A Double-blind, Randomised, Placebo-controlled, Parallel Group, Multi-centre Study.
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
New York, NY
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects With Overactive Bladder and a Diagnosis of Detrusor Overactivity - A Double-blind, Randomised, Placebo-controlled, Parallel Group, Multi-centre Study.
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects With Overactive Bladder and a Diagnosis of Detrusor Overactivity - A Double-blind, Randomised, Placebo-controlled, Parallel Group, Multi-centre Study.
Status: Enrolling
Updated:  2/15/2017
Clinical Research Facility
mi
from
West Reading, PA
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects With Overactive Bladder and a Diagnosis of Detrusor Overactivity - A Double-blind, Randomised, Placebo-controlled, Parallel Group, Multi-centre Study.
Status: Enrolling
Updated: 2/15/2017
Clinical Research Facility
mi
from
West Reading, PA
Click here to add this to my saved trials
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects With Overactive Bladder and a Diagnosis of Detrusor Overactivity - A Double-blind, Randomised, Placebo-controlled, Parallel Group, Multi-centre Study.
Status: Enrolling
Updated:  2/15/2017
509
mi
from
Graz,
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects With Overactive Bladder and a Diagnosis of Detrusor Overactivity - A Double-blind, Randomised, Placebo-controlled, Parallel Group, Multi-centre Study.
Status: Enrolling
Updated: 2/15/2017
509
mi
from
Graz,
Click here to add this to my saved trials
Precise Transvaginal Tape Placement Trial
Precise Transvaginal Tape Placement Trial
Status: Enrolling
Updated:  2/28/2017
Loyola University Health System
mi
from
Maywood, IL
Precise Transvaginal Tape Placement Trial
Precise Transvaginal Tape Placement Trial
Status: Enrolling
Updated: 2/28/2017
Loyola University Health System
mi
from
Maywood, IL
Click here to add this to my saved trials
The Effect of an Additional Stress Incontinence Procedure on Overactive Bladder During Pelvic Organ Prolapse Repair
The Effect of an Additional TVT on OAB Symptoms in Surgical Repair of Pelvic Organ Prolapse
Status: Enrolling
Updated:  8/31/2017
Mount Sinai Hosp
mi
from
New York, NY
The Effect of an Additional Stress Incontinence Procedure on Overactive Bladder During Pelvic Organ Prolapse Repair
The Effect of an Additional TVT on OAB Symptoms in Surgical Repair of Pelvic Organ Prolapse
Status: Enrolling
Updated: 8/31/2017
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Status: Enrolling
Updated:  10/3/2017
Urologic Clinics of North Alabama
mi
from
Huntsville, AL
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Status: Enrolling
Updated: 10/3/2017
Urologic Clinics of North Alabama
mi
from
Huntsville, AL
Click here to add this to my saved trials
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Status: Enrolling
Updated:  10/3/2017
Alaska Urological Institute DBA Alaska Clinical Research Center
mi
from
Anchorage, AK
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Status: Enrolling
Updated: 10/3/2017
Alaska Urological Institute DBA Alaska Clinical Research Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Status: Enrolling
Updated:  10/3/2017
South Orange County Medical Research Center
mi
from
Laguna Hills, CA
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Status: Enrolling
Updated: 10/3/2017
South Orange County Medical Research Center
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Status: Enrolling
Updated:  10/3/2017
University of Southern California
mi
from
Los Angeles, CA
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Status: Enrolling
Updated: 10/3/2017
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Status: Enrolling
Updated:  10/3/2017
Genesis Research
mi
from
San Diego, CA
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Status: Enrolling
Updated: 10/3/2017
Genesis Research
mi
from
San Diego, CA
Click here to add this to my saved trials